Compression Behavior of Micronized Prednisolone in Low-Dose Veterinary Tablets

Low-dose prednisolone tablets for companion animals are typically produced at potencies of 1 mg, 2.5 mg, 5 mg, and 10 mg per unit. The active pharmaceutical ingredient is a non-sterile crystalline base with practically no aqueous solubility. Because the dose-to-tablet weight ratio is low, direct compression demands strict particle size control. Air-jet milling is used to reduce the particle size distribution to a D90 in the region of 15 µm to 30 µm. This target is not a compendial limit but a supplier-method acceptance range derived from content uniformity studies. Laser diffraction measurement per USP <429> is used to monitor the particle size distribution. The milled API is protected from moisture at above 60% RH during warehousing and dispensing. Exposure to elevated humidity can cause aggregation and impair downstream blend uniformity.

Excipient selection for direct compression includes microcrystalline cellulose, lactose monohydrate, crospovidone, colloidal silicon dioxide, and magnesium stearate. A two-stage blending sequence is used. The API is first triturated with an equal volume of microcrystalline cellulose and passed through a 600 µm stainless steel screen. The screened premix is then loaded into a V-blender. The main excipient fraction is added in two equal parts with blending at 25 rpm for 20 min between additions. Magnesium stearate is added at 0.5% to 1.0% w/w and blended for 3 min to 5 min. Blending beyond 5 min with magnesium stearate is avoided because overlubrication lowers tablet hardness and delays disintegration. Content uniformity acceptance value is measured per USP <905>. The acceptance criterion is AV ≤ 15.0. In-process evaluation uses assay of 10 stratified samples collected from the blender discharge. A validated HPLC method is used for assay and related substances.

Compression is carried out on a rotary tablet press equipped with 6.0 mm round flat-faced bevel-edge punches. Tablet weight is typically set between 80 mg and 120 mg depending on potency. Compression force is adjusted to achieve hardness of 6 kp to 9 kp as measured by a Schleuniger hardness tester. Friability is checked by rotating 10 tablets in a friabilator for 100 revolutions. The limit is less than 1.0% weight loss per USP <1216>. Disintegration time in water at 37 °C is typically below 15 min using disks. Tablets are packaged in amber HDPE bottles with silica gel desiccant units. The desiccant is used because prednisolone tablets stored above 60% RH may develop surface film formation and dissolution drift. Dissolution is tested with USP <711> Apparatus 2 at a paddle speed of 50 rpm to 75 rpm. The medium is 900 mL of dilute sodium lauryl sulfate solution. Surfactant is necessary because the base form has negligible solubility in plain water. The registered product dossier defines the exact Q value at the 30 min sampling point. A typical acceptance criterion is not less than 80% dissolved at 30 min.

Published industrial data for this exact low-dose veterinary prednisolone formulation is limited. Batch-specific compression and blending parameters are confirmed through manufacturer design-of-experiments programs rather than universal adoption of fixed ranges. This limitation is stated to avoid overextending compendial test conditions into unvalidated process space.

In sterile suspension manufacture, the non-sterile veterinary prednisolone API is not introduced directly into the aseptic filling line without prior reduction of bioburden and endotoxin load. The base form is used for suspension injections because it is practically insoluble and provides a depot effect after intramuscular or intra-articular administration. The crystalline API is subjected to a validated reduction step. Dry heat at 160 °C for 2 h may be acceptable only when confirmed by HPLC assay and related substance monitoring. The dihydroxyacetone side chain undergoes oxidative degradation when exposed to excessive heat. Gamma irradiation at a validated dose can be used as an alternative. The sterilized API is milled aseptically to a D50 target appropriate for parenteral suspensions. Routine particle size analysis is performed by laser diffraction according to USP <429>. Injectability requires control of both particle size and aggregate size. The vehicle is prepared separately using water for injection, polysorbate 80, sodium chloride, and a suspending agent such as sodium carboxymethylcellulose. The vehicle is heat sterilized by moist heat at 121 °C for 20 min. The sterile API is then dispersed aseptically under high-shear mixing. The mixer is a rotor-stator homogenizer operated at speeds from 8000 rpm to 12000 rpm. Mixing is followed by low-speed propeller agitation to prevent foam.

Final product testing includes sterility per Ph. Eur. 2.6.1 or USP <71>. Bacterial endotoxin limit is calculated from the maximum labeled dose and tested by the kinetic chromogenic method per Ph. Eur. 2.6.14 or USP <85>. Preservative effectiveness is required for multi-dose presentations and is evaluated by Ph. Eur. 5.1.3 or USP <51>. Subvisible particulate matter testing per USP <788> is more difficult for suspensions because the formulation contains particles by design. In such cases, light obscuration is not routinely used. Particle size distribution, syringeability, and aggregate content are controlled instead. The pH is maintained between 6.0 and 7.5 because alkaline and acidic extremes accelerate hydrolysis of the C21 ketol side chain. For solution injections, the sodium phosphate ester rather than the base is used. The solution is buffered to near neutral pH and filtered through a 0.22 µm polyvinylidene fluoride membrane filter. Terminal steam sterilization is avoided for corticosteroid solutions due to chemical degradation. The entire process is run in a closed isolator to avoid operator exposure and contamination.

Why Does Dry Granulation Protect Prednisolone From Hydrolytic Degradation During Capsule and Granule Production?

Prednisolone base is practically insoluble in water and exhibits poor bulk flow in the unmilled state. Wet granulation with aqueous binders is avoided because the low-solubility crystals remain undissolved but can redistribute during drying, causing non-uniform agglomerate composition. Aqueous processes also create sticky bridge defects when the API is micronized. Dry granulation by roller compaction solves both flow and segregation problems without adding moisture. The process is used to produce granules for veterinary capsules and for sachet-style oral powders. The API is pre-blended with lactose monohydrate, microcrystalline cellulose, and crospovidone. The pre-blend is then passed through a roller compactor equipped with a horizontal feed screw. Ribbon solid fraction is the main quality attribute. A target solid fraction of 0.60 to 0.70 is determined by mercury intrusion porosimetry or helium pycnometry. Roll gap is commonly set between 2.0 mm and 3.0 mm. Roll pressure is not used as a fixed universal value because feed screw speed, roll surface finish, and air humidity influence ribbon density. The ribbon is milled through an oscillating granulator fitted with a 0.8 mm to 1.0 mm stainless steel screen. The resulting granules are screened through a 40-mesh sieve with a 425 µm aperture, and the oversize fraction is remilled. Granules that pass through a 100-mesh sieve with a 150 µm aperture are recycled only in a controlled ratio because too many fines reduce flow improvement.

The granulation suite must be maintained below 60% RH. Above this threshold, ribbon sticking to the rollers increases and the compaction force becomes unstable. Batch records include loss on drying by USP <731>, with a maximum limit of 2.0% water content. Flowability is tested by measuring bulk and tapped density per USP <616>. The Hausner ratio is calculated from these measurements. A value below 1.25 is generally required for consistent capsule filling. Powder flow is also assessed by the angle of repose or by USP <1174> methods. Granule size distribution is determined by sieve analysis. The process is validated through content uniformity of the milled granules. Ten stratified samples are collected from the granulator discharge. The relative standard deviation of prednisolone assay is used to set final blending time. If the granule RSD exceeds 5.0%, the extra-granular blending time in a bin blender is extended until uniform. The dry granulation route is preferred for moisture-sensitive packaging because no drying step is required. The finished granules are filled into hard gelatin capsules or sealed sachets using standard powder filling equipment. Low moisture condition reduces microbial growth potential and hydrolytic degradation during storage.

Oral treatment of poultry and swine through drinking water requires either a water-soluble prednisolone derivative or a coarse-dispersible base powder with controlled hydration kinetics. Prednisolone sodium phosphate is the usual choice for clear drinking water solutions because the phosphate ester ionizes readily at neutral pH. The base form is used only for suspension-type oral powders where the label instructs vigorous stirring before administration. A typical oral powder formulation includes the API, a buffering salt such as dibasic sodium phosphate, and a filling agent such as lactose monohydrate or dextrose. A chelating agent such as edetate disodium is included at low concentration because trace metal ions in hard water accelerate oxidative degradation of the corticosteroid side chain. The dry blend is filled into aluminum foil sachets under nitrogen to limit residual oxygen. The fill weight is calculated to deliver the prescribed mg/kg daily dose in the drinking water volume consumed over a 24 h period. No fixed concentration is universally valid across species and production systems. Assay after reconstitution must fall between 90.0% and 110.0% of label claim. Reconstitution is performed in a paddle-mixed tank with water at 20 °C to 25 °C. Turbulence is maintained for 5 min to 10 min.

Aqueous stability is limited by pH shifts. Below pH 5.0, the sodium phosphate ester may hydrolyze to the base, causing precipitation. Above pH 7.5, the C21 side chain may undergo degradation. The formulation buffer therefore maintains a pH between 6.0 and 7.5. Drinking water systems containing metal pipes may introduce iron and copper ions. These ions promote oxidation unless the chelating agent has been included. In-use solutions should be consumed within 24 h when stored at ambient temperature. At temperatures above 30 °C, the in-use period is shortened to 12 h. The solution is dispensed through a proportioning pump with calibrated flow rate. The pump calibration is verified before each treatment batch. Lines and nipple drinkers are flushed after each treatment cycle to prevent carry-over. Cleaning validation uses rinse water sampling and HPLC assay. The acceptance limit for carry-over is not more than 0.1% of the previous batch concentration. Packaging and stability studies follow VICH GL requirements for veterinary medicinal products in aqueous reconstituted form. The liquid phase is protected from light by using amber stock solutions or opaque intermediate bulk containers.

Premix Dilution Geometry, Mixer Validation, and Segregation Risk in Feed-Scale Blending

Feed-grade prednisolone premix is diluted from the concentrated API by stepwise blending because direct addition of micronized active material to a large ribbon mixer produces unacceptable assay variance. The first dilution stage is usually a 1% w/w active premix prepared with lactose monohydrate or corn starch in a small bin blender. The second stage is a 0.1% w/w premix for direct addition to complete feed. The geometric dilution ratio is selected so that each stage does not exceed a 1:10 active-to-carrier ratio. Carrier particle size is matched to the API to reduce segregation. A carrier D50 between 150 µm and 250 µm is common. The carrier surface roughness and oil absorption capacity are evaluated because micronized prednisolone adheres more readily to porous carriers. A food-grade vegetable oil is sometimes added at 0.5% to 1.0% w/w as a binder to reduce dust and improve adhesion. If oil is used, the peroxide value of the oil must be controlled because oxidative breakdown products destabilize prednisolone. The blend is passed through a 30-mesh sieve with a 600 µm aperture before use.

Mixer validation is conducted using an approved sampling plan. Samples are collected according to ISO 6497:2002. The coefficient of variation for prednisolone assay across 10 to 20 defined sampling locations is required to be ≤ 5.0% for routine release. Sampling points include the mixer discharge, the top region, and the geometric center. A validated HPLC method is used for assay. Recovery from feed is checked by spiking blank feed with known amounts of prednisolone. The method recovery should be between 95.0% and 105.0%. The lower limit of quantification is set below 10% of the target concentration. Cleanout validation is performed after each batch because corticosteroids can persist in ribbon mixer seals and dead zones. The acceptance limit for carry-over is not more than 0.1% of the next batch concentration. Mixing time is not fixed universally. A mixing time profile is generated by sampling at 5 min, 10 min, 15 min, and 20 min. The time at which the assay RSD falls below 5.0% and remains stable is selected. Overmixing can increase segregation when the blend contains particles with widely different densities. The finished premix is packaged in multi-wall paper bags with an inner polyethylene liner. The liner is sealed with a dry air purge to reduce moisture ingress.

When Custom Capsule Compounding Uses Bulk Veterinary API in Non-Sterile Pharmacy Settings, Contamination Control Steps Apply

When bulk veterinary prednisolone API is compounded into capsules outside a licensed pharmaceutical plant, the operation falls under non-sterile compounding requirements rather than full registered manufacturing. The applicable standards include USP <795> for non-sterile compounding and USP <800> for hazardous drug handling. Prednisolone is classified as a hazardous drug because corticosteroids can cause occupational exposure effects. All compounding steps are performed in a negative-pressure containment hood with powder-containment controls. The operator uses double nitrile gloves and a closed transfer device for large quantities. Weighing is done on an analytical balance with a readability of 0.1 mg. The minimum weighable quantity is calculated according to USP <1251>. The formula is based on balance repeatability and the required accuracy percentage. The pharmacy must not weigh a quantity below the accepted minimum because dose error becomes large.

The actual compounding uses geometric dilution. A small quantity of API is triturated with an equal volume of lactose monohydrate in a glass mortar. The process is repeated until all diluent has been incorporated. The mixture is passed through a 40-mesh sieve with a 425 µm aperture. A mortar and pestle dedicated only to prednisolone is recommended. Hard gelatin capsules are filled manually with a capsule filling machine. The powder density and flow properties are adjusted only with lactose or microcrystalline cellulose. Lubricants are usually omitted to avoid complicating dissolution in a non-validated formulation. Each capsule is individually weighed. The allowable deviation depends on the finished capsule weight. For a typical 150 mg to 250 mg fill weight, the individual weight variation is controlled within ±5.0%. This is based on Ph. Eur. 2.9.5 mass variation requirements for capsules as a practical in-process check. Capsules are stored in amber containers with desiccant silica gel. The storage temperature is below 25 °C. The pharmacy must perform a surface wipe test after each compounding session. The analytical method uses HPLC with a limit of detection low enough to verify decontamination. No food or drink is allowed in the compounding enclosure. The compounding log must record the API supplier lot number, the balance calibration date, and the relative humidity. Above 60% RH, the API may form lumps and the capsule fill weight becomes inconsistent. In those conditions, the compounding area should be dehumidified before processing.